For Most Biotechs, the Tough Times Continue

There is always considerable chatter about the health of the biotech industry and, despite individual tales and stock-picking speculation, the overall assumption continues to be that many companies are finding it difficult to raise money, generate revenue and simply keep the lights on. But what is the reality? In some respects, the hard times continue, but the picture is a bit mixed, actually, depending upon company size and a few other variables.